Browse by People

Collapse authors list.
Kudo, Masatoshi, Ueshima, Kazuomi, Ikeda, Masafumi, Torimura, Takuji, Tanabe, Nobukazu, Aikata, Hiroshi, Izumi, Namiki, Yamasaki, Takahiro, Nojiri, Shunsuke, Hino, Keisuke et al (show 17 more authors) , Tsumura, Hidetaka, Kuzuya, Teiji, Isoda, Norio, Moriguchi, Michihisa, Aino, Hajime, Ido, Akio, Kawabe, Naoto, Nakao, Kazuhiko, Wada, Yoshiyuki, Ogasawara, Sadahisa, Yoshimura, Kenichi, Okusaka, Takuji, Furuse, Junji, Kokudo, Norihiro, Okita, Kiwamu, Johnson, Philip James ORCID: 0000-0003-1404-0209 and Arai, Yasuaki (2022) Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarteria Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. LIVER CANCER, 11 (4). pp. 354-367.

Collapse authors list.
Kudo, Masatoshi, Ueshima, Kazuomi, Ikeda, Masafumi, Torimura, Takuji, Tanabe, Nobukazu, Aikata, Hiroshi, Izumi, Namiki, Yamasaki, Takahiro, Nojiri, Shunsuke, Hino, Keisuke et al (show 18 more authors) , Tsumura, Hidetaka, Kuzuya, Teiji, Isoda, Norio, Yasui, Kohichiroh, Aino, Hajime, Ido, Akio, Kawabe, Naoto, Nakao, Kazuhiko, Wada, Yoshiyuki, Yokosuka, Osamu, Yoshimura, Kenichi, Okusaka, Takuji, Furuse, Junji, Kokudo, Norihiro, Okita, Kiwamu, Johnson, Philip James ORCID: 0000-0003-1404-0209, Arai, Yasuaki and TACTICS study group, (2020) Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut, 69 (8). pp. 1492-1501.

Collapse authors list.
Kudo, Masatoshi, Ueshima, Kazuomi, Yokosuka, Osamu, Ogasawara, Sadahisa, Obi, Shuntaro, Izumi, Namiki, Aikata, Hiroshi, Nagano, Hiroaki, Hatano, Etsuro, Sasaki, Yutaka et al (show 13 more authors) , Hino, Keisuke, Kumada, Takashi, Yamamoto, Kazuhide, Imai, Yasuharu, Iwadou, Shouta, Ogawa, Chikara, Okusaka, Takuji, Kanai, Fumihiko, Akazawa, Kohei, Yoshimura, Ken-ichi, Johnson, Philip ORCID: 0000-0003-1404-0209, Arai, Yasuaki and SILIUS Study Group, (2018) Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. LANCET GASTROENTEROLOGY & HEPATOLOGY, 3 (6). pp. 424-432.